Last reviewed · How we verify
Nurofen for Children®
At a glance
| Generic name | Nurofen for Children® |
|---|---|
| Also known as | Ibuprofen orange oral suspension, NfC® |
| Sponsor | Reckitt Benckiser Healthcare (UK) Limited |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Ibuprofen 4% (w/v) Pivotal Bioequivalence Study (PHASE1)
- Bioequivalence Study of Ibuprofen D, Oral Suspension, 200 mg/5ml and Nurofen®, Oral Suspension 100 mg/5 ml in Healthy Volunteers Under Fasting Conditions (PHASE1)
- Ibuprofen Suspension Bioequivalence Study (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nurofen for Children® CI brief — competitive landscape report
- Nurofen for Children® updates RSS · CI watch RSS
- Reckitt Benckiser Healthcare (UK) Limited portfolio CI